Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPSE | Q9Y251 | 6/20 | 0.47 |
| ▸ | FGF1 | P05230 | 5/20 | 0.47 |
| ▸ | FGF2 | P09038 | 5/20 | 0.47 |
| ▸ | VEGFA | P15692 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | IGF2R | P11717 | 4/20 | 0.42 |
| ▸ | PTN | P21246 | 1/20 | 0.39 |
| ▸ | MDK | P21741 | 1/20 | 0.39 |
| ▸ | BDNF | P23560 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8150299 | 0.90 | IGF2R (0.53) | HPSEFGF1FGF2VEGFAMAPK1 | |
| SCHEMBL17167553 | 0.84 | BDNF (0.55) | HPSEFGF1FGF2VEGFAPTN | |
| SCHEMBL17167539 | 0.82 | BDNF (0.51) | HPSEFGF1FGF2VEGFAPTN | |
| SCHEMBL17167541 | 0.81 | BDNF (0.54) | HPSEFGF1FGF2VEGFAPTN | |
| SCHEMBL17208466 | 0.81 | SELP (0.42) | HPSEFGF1FGF2VEGFAMAPK1 | |
| SCHEMBL24041056 | 0.80 | MAPK1 (0.62) | MAPK1 | |
| SCHEMBL15304380 | 0.80 | MAPK1 (0.62) | MAPK1 | |
| SCHEMBL18349786 | 0.79 | GJB2 (0.49) | MAPK1IGF2R | |
| SCHEMBL18915088 | 0.78 | HPSE (0.44) | HPSEFGF1FGF2VEGFAMAPK1 | |
| SCHEMBL17208461 | 0.77 | MAPK1 (0.64) | HPSEVEGFAMAPK1PTNMDK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170152279-A9 | Saccharide Dendritic Cluster Compounds as Inhibitors of Bace-1 | UNIVERSITY OF LIVERPOOL (GB) | 2017-06-01 | — | — | US | disclosed |
| US-20150291644-A1 | Saccharide Dendritic Cluster Compounds as Inhibitors of Bace-1 | VICTORIA LINK LTD (NZ) | 2015-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291644-A1 | Saccharide Dendritic Cluster Compounds as Inhibitors of Bace-1 | BACE1, BACE2, APP | HPSE 134/4885FGF1 1768/4885FGF2 2224/4885 |
| US-20170152279-A9 | Saccharide Dendritic Cluster Compounds as Inhibitors of Bace-1 | BACE1, BACE2, APP | HPSE 134/4885FGF1 1768/4885FGF2 2224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.